Spero Therapeutics, Inc.
SPRO
Positions held
Your positionsSPRO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $66.39M | Enterprise value | $17.66M | Trailing P/E | 8.14 | Forward P/E | -1.03 |
| PEG | — | Price / book | 1.50 | Beta | 1.50 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 56.3% | Operating margin | 14.1% |
| Profit margin | 15.7% | ROE | 19.2% | ROA | 7.2% | Debt / equity | 0.05 |
| Current ratio | 6.12 | Free cash flow | $28.85M | Analyst recommendation | none | Mean target | $5.00 |
| 52w high | $3.08 | 52w low | $1.08 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.3M | $39.7M | $3.0M | $11.8M | — |
| Op margin | — | -2921.7% | 79.2% | -240.5% | -20.0% | — |
| Net income | -$9.6M | -$7.2M | $31.5M | -$7.4M | -$1.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.9M | -$7.5M | $31.4M | -$7.3M | -$2.4M | — |
- Revenue -100% vs prior quarter ($0 vs $0.3M).
- Operating margin compressed to -2921.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $59.6M | $27.4M | $96.7M | $48.6M | — |
| Op margin | 12.0% | -264.6% | 27.7% | -62.9% | — |
| Net income | $8.6M | -$68.6M | $22.8M | -$46.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $7.2M | -$72.5M | $26.8M | -$30.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 · Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-19 · Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
2026-08-13 · Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
2026-08-13 · Spero Therapeutics Q2 Earnings Call Highlights
2026-08-12 · Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
2026-08-05 · Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-04 · Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
2026-07-27 · Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
2026-07-15 · Innovent licenses IBI355 rights to Spero for up to $1.1bn
Price (daily)
Full chart · RSI · MACD · patterns